Sugi Predict

Sugi Predict / Compounds / SCHEMBL1151024

SCHEMBL1151024

SCHEMBL1151024

CC1CCCCN1C(=O)Cn1ccn2c(=O)c(O)c(-c3ncc(Cc4ccc(F)cc4)s3)nc12

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ KMT2A Q03164 1/20 0.40
▸ ALDH1A1 P00352 5/20 0.38
▸ POLB P06746 1/20 0.38
▸ LMNA P02545 3/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ TSHR P16473 2/20 0.37
▸ HPGD P15428 2/20 0.35
▸ TP53 P04637 4/20 0.35
▸ USP2 O75604 1/20 0.34
▸ CPT1A P50416 1/20 0.34
▸ MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12874999 0.88 KMT2A (0.40) SMN1; SMN2KMT2AALDH1A1POLBLMNA
SCHEMBL1151504 0.88 SMN1; SMN2 (0.39) SMN1; SMN2KMT2AALDH1A1POLBLMNA
SCHEMBL1151351 0.87 SMN1; SMN2 (0.39) SMN1; SMN2KMT2AALDH1A1POLBLMNA
SCHEMBL12862300 0.87 GRIN2B (0.39) SMN1; SMN2KMT2AALDH1A1TP53
SCHEMBL1150882 0.84 RAB9A (0.36) SMN1; SMN2KMT2AALDH1A1LMNANPC1
SCHEMBL13522716 0.84 GRIN2B (0.34) SMN1; SMN2
SCHEMBL1150416 0.84 SMN1; SMN2 (0.37) SMN1; SMN2KMT2AALDH1A1POLBLMNA
SCHEMBL12862323 0.84 GRIN2B (0.39) SMN1; SMN2KMT2AALDH1A1LMNANPC1
SCHEMBL1150415 0.84 SMN1; SMN2 (0.37) SMN1; SMN2KMT2AALDH1A1POLBLMNA
SCHEMBL12862245 0.84 GRIN2B (0.39) SMN1; SMN2KMT2AALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2291377-B1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LTD (AU) 2015-02-18 — — EP disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 — — US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 — — US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 — — US disclosed
EP-2291377-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF Avexa Limited (AU) 2011-03-09 — — EP disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 — — US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 — — US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 — — US disclosed
WO-2010000031-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 — — WO disclosed
WO-2010000031-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF TPMT, DPYD, IMPDH1 SMN1; SMN2 958/4885KMT2A 1900/4885ALDH1A1 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.